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Meaningful interpretation of metabolic images obtained by 
positron emission tomography for evaluation of cardiac disease 
requires a knowledge of the normal variation in regional myocar-
dial substrate metabolism. Recent studies with fluorine-18 (F -18) 
fluorodeoxyglucose suggest inhomogeneity of myocardial glucose 
metabolism in the normal human heart, which may relate to 
substrl.lte availability. Therefore, quantitative evaluation of myo-
cardial' oxidative metabolism and glucose metabolism, as derived 
by dynamic positron emission tomography with carbon-11 (C-11) 
acetate and F -18 fluorodeoxyglucose, was performed in nine 
healthy male volunteers. AU were studied under tightly controlled 
metabolic conditions of hyperinsulinemic-euglycemic clamping 
with and without a concurrent lipid emulsion infusion. 
Significant inhomogeneity of regional glucose metabolism was 
noted although it was less than that described under fasting 
conditions. Glucose utilization was 13% lower in the septum 
In vivo studies (1) of myocardial metabolism in the normal 
human heart using coronary sinus sampling have provided 
elegant characterization of myocardial metabolism but have 
been confined to assessment of global substrate extraction. 
Positron emission tomography in combination with meta-
bolic tracers provides a unique opportunity to evaluate 
regional myocardial metabolism in vivo. The ability to 
noninvasively characterize the three-dimensional distribu-
tion of myocardial oxidative and glucose metabolism has 
recently become possible because of advances in positron 
emission tomographic imaging systems, analysis software 
and positron-emitting radiopharmaceutical development. 
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compared with the lateral wall both without and with lipid 
infusion (0.34 vs. 0.39 pIllollg per min, respectively, p < 0.05; and 
0.33 vs. 0.38 pIllollg per min, respectively, (p < 0.05). Relatively 
decreased septal glucose utilization could not be explained by 
decreased metabolic demand because C-11 clearance constants 
were marginally higher in the septum than in the lateral wall in 
both studies (0.055 vs. 0.054 per min, respectively, p = NS; and 
0.061 vs. 0.056 per min, respectively, p < 0.05). Relatively 
decreased septal glucose utilization could reflect regional variation 
in substrate use and possible preferential free fatty acid utilization 
by the septum. 
These data provide a useful framework for assessing altered 
cardiac metabolism in disease and support standardization of 
metabolic conditions during metabolic imaging with positron 
emission tomography. 
(1 Am Coil CardioI1991;18:101-11) 
Current generation, multi slice positron emission tomo-
graphic instrumentation permits simultaneous imaging of the 
entire heart. Also, newly developed software allows stan-
dardized reorientation of such three-dimensional dynamic 
data sets into a temporal series of orthogonal projections 
aligned to the cardiac long axis (2). Moreover, myocardial 
metabolism can be quantitated using mathematic modeling 
of tracer kinetics. For example, carbon-II (C-Il) acetate has 
recently been introduced and validated as a tracer of myo-
cardial oxidative metabolism (3-7), supplying quantitative, if 
not absolute, evaluation of regional myocardial oxygen 
consumption (2). Similarly, the metabolic handling of fluo-
rine-I8 (F-I8) fluorodeoxyglucose allows simplified compart-
mental modeling (8) and quantification of exogenous myo-
cardial glucose utilization (9,10). 
With the wider application of these positron-emitting 
tracers for the assessment of cardiac disease, a knowledge of 
the homogeneity of their kinetic handling by the heart and its 
dependence on metabolic conditions is crucial for the inter-
pretation of pathologic change in myocardial metabolism. 
This knowledge is of particular importance because recent 
qualitative (11,12) and semiquantitative studies (13) using 
positron emission tomography have suggested that there 
may be regional variation of myocardial glucose metabolism 
within the normal human heart that may relate to substrate 
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Figure 1. The study protocol for two series of positron emission 
tomographic (PET) imaging with sequential C-ll acetate and F-18 
fluorodeoxyglucose (FDG) studies under standardized metabolic 
conditions. The only difference between the two protocols was the 
addition of a lipid emulsion infusion (Liposyn 20%) in the Day 2 
protocol to elevate free fatty acid levels. FFA = free fatty acid; 
IV = intravenous. 
availability. Specifically, Gropler et al. (13) described inho-
mogeneity of F-18 fluorodeoxyglucose retention that was 
most marked under fasting conditions, possibly reflecting the 
effect of elevated free fatty acid levels in this state. The 
present study was performed to quantitatively evaluate and 
compare the regional homogeneity of glucose and oxidative 
metabolism in the normal heart under standardized but 
varied conditions of substrate availability. 
Methods 
Subject preparation. The study protocol was approved 
by the Human Subject Protection Committee of the Univer-
sity of Michigan Medical Center. Nine healthy male volun-
teers, 22 to 38 years of age (mean ± SD 27 ± 6), were 
enrolled after granting informed written consent. All were 
nonsmokers. None had metabolic or cardiac disease based 
on clinical history, physical examination or laboratory test-
ing. Before being accepted for the study, all subjects were 
required to have a normal rest electrocardiogram (ECG) and 
oral glucose tolerance test and to be within 20% of ideal body 
weight (14). 
Before each series of positron emission tomographic 
studies, an intravenous line was placed in the antecubital 
fossa. This was used for infusions and administration of 
radioisotopes. Another intravenous line was placed retro-
gradely in a dorsal vein of the contralateral hand and was 
used for blood sampling. 
Study protocol (Fig. 1). The study was designed to eval-
uate and compare regional myocardial glucose and oxidative 
metabolism under standardized metabolic conditions of glu-
cose and insulin loading. The glucose-loaded state was 
chosen because clinical F-18 fluorodeoxyglucose positron 
emission tomographic studies are generally performed after 
an oral glucose load that has been shown (12) to stimulate 
F-18 fluorodeoxyglucose uptake by the myocardium. Oral 
glucose loading is associated with significant fluctuation in 
serum glucose and insulin levels over time, potentially 
limiting the quantitative evaluation and valid comparison of 
myocardial metabolism using tracer approaches. Therefore, 
an insulin clamp procedure, as described by DeFronzo et al. 
(15), was used to minimize temporal variation in metabolic 
conditions during and between metabolic imaging studies 
with positron emission tomography. 
The independent effect of increased free fatty acid avail-
ability on regional myocardial metabolism in the glucose-
and insulin-loaded state was assessed by performing studies 
both without and with a concurrent lipid emulsion infusion 
(Liposyn 20% at 1 mllmin) in each subject. These two 
studies, each including sequential C-11 acetate and F-18 
fluorodeoxyglucose imaging, were separated by 1 to 21 days 
(Fig. 1). This was considered to be important because free 
fatty acids are the major alternative myocardial substrate to 
glucose (1,16) and have been shown to both increase global 
myocardial oxygen consumption (17) and decrease glucose 
extraction by the normal myocardium under fasting condi-
tions (18-20). Moreover, Gropler et al. (13) found that 
inhomogeneity of F-18 fluorodeoxyglucose retention was 
most marked under fasting conditions when free fatty acid 
levels were likely to have been increased. 
Standardization of metabolic conditions. Metabolic condi-
tions throughout positron emission tomographic imaging 
were controlled by using a hyperinsulinemic-euglycemlc 
clamp (15). All subjects fasted overnight before the study. 
Intravenous tubing was primed and flushed with insulin 
solution to minimize the effects of adsorption of insulin onto 
plastic. Next, regular human insulin in 0.9% sodium chloride 
was infused as a bolus and then at a constant rate that was 
calculated on the basis of the SUbject's body mass to achieve 
a plasma insulin level of 80 to 120 IU/liter (15). These levels 
are similar to the plasma insulin levels achieved in normal 
subjects 1 h after a 75 g oral glucose load. Plasma for analysis 
of glucose levels was drawn at 5 min intervals and measured 
using an automated glucose analyzer (Beckman Instru-
ments). On the basis of these levels, glucose (20% dextrose 
with 5 mEq potassium chloride/500 ml) was infused at a 
variable rate until a steady state plasma glucose level of 
about 85 mg/dl was obtained. Equilibration of plasma glu-
cose level was achieved in <45 min after commencement of 
the insulin and glucose infusions in all individuals. Baseline 
glucose levels in study subjects were only slightly higher 
than the target level (averaging 93 ± 6 mg/dl before the initial 
clamp study and 92 ± 5 mg/dl before the second study in 
each individual). 
The second series of positron emission tomographic 
studies in each individual subject was done during a concur-
rent lipid emulsion infusion (Liposyn 20% at 1 mllmin) to 
increase circulating levels of free fatty acids. All subjects 
had a 30 min test dose (Liposyn 20% at 0.5 mllmin) before 
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starting the second insulin clamp to exclude hypersensitivity 
to Liposyn. 
Evaluation of metabolic conditions. Venous blood was 
arterialized by placing the subject's hand in a hot box to 
assess arterial substrate and hormone levels without needing 
arterial puncture. This technique minimizes the possible 
effects of skeletal muscle extraction of these substances by 
increasing cutaneous blood flow and effectively producing 
arteriovenous shunting of blood. The results obtained in this 
way accurately reflect arterial concentrations (21-23). Blood 
samples were drawn at baseline, at the beginning and the end 
of the C-l1 acetate study and at the beginning, mid-point and 
end of the F-18 fluorodeoxyglucose study and were frozen 
until analyzed. Glucose, free fatty acids, insulin, lactate, 
glucagon, growth hormone and catecholamines were mea-
sured from these samples using previously published tech-
niques (24-32). These data were used to assess the compa-
rability of metabolic conditions during each imaging 
sequence and evaluate possible effects of each of these 
substrates and hormones on myocardial C-l1 acetate and 
F-18 fluorodeoxyglucose kinetics for paired studies in each 
subject. All patients had their heart rate and blood pressure 
recorded at 15 min intervals and ECG monitoring performed 
throughout the investigation. 
Positron emission tomography acquisition protocol. 
Positron emission tomography with C-ll acetate and F-18 
fluorodeoxyglucose was performed using a whole body 
positron emission tomographic scanner (Siemens 931, CTI), 
allowing the simultaneous imaging of 15 transaxial slices 
(6.75 mm thick) encompassing the entire heart. Transmission 
images, used for attenuation correction of the emission 
images, were acquired for 15 min during stabilization of the 
plasma glucose level. The C-ll acetate was synthesized 
using a modification of the technique described by Pike et al. 
(3) and C-ll acetate studies were begun when the plasma 
glucose level had stabilized at the target level of about 85 
mg/dl, which occurred 45 to 60 min after beginning the 
insulin clamp procedure (Fig. 1). Imaging was performed 
after intravenous administration of 740 MBq (20 mCi) over 
30 s. Dynamic positron emission tomographic images were 
obtained for 31 min, with 10 frames of 90 s duration followed 
by 5 frames of 120 s duration and 2 frames of 180 s duration. 
After the C-11 acetate study, 30 min was allowed for 
decay and clearance of residual C-l1 activity from the blood 
pool and myocardium. Dynamic positron emission tomo-
graphic imaging was then performed for 1 h after intravenous 
administration of 370 MBq (10 mCi) of F-18 fluorodeoxyglu-
cose. Twelve frames of 5 min duration were obtained (Fig. 
1). F-18 fluorodeoxyglucose had been synthesized using 
previously described methods (33). 
Regional analysis algorithms. A reorientation algorithm 
was used to generate a dynamic series of 12 short-axis 
cardiac planes from the dynamic series of 15 transaxial 
planes obtained in the C-ll acetate and F-18 fluorodeoxy-
glucose studies. This reorientation algorithm involves a 
linear interpolation of activity data. The reoriented short-
axis cardiac images served as input data to semiautomated 
regional analysis programs, newly developed at our institu-
tion, that create polar coordinate maps of myocardial C-ll 
clearance rate constants and myocardial glucose utilization. 
Early steps in the analysis of the C-11 acetate and F-18 
fiuorodeoxyglucose studies were similar. 1) Epicardial and 
endocardial ellipses were assigned by the operator for each 
short-axis plane in the frame (defined as a set of short-axis 
planes acquired simultaneously as part of a dynamic series) 
with the highest ratio of cardiac to noncardiac activity. In the 
C-l1 acetate study, this was an early frame obtained soon 
after the rapid phase of blood pool clearance and before 
significant clearance of myocardial C-ll activity. In the F-18 
fluorodeoxyglucose study, the final frame was chosen as a 
result of progressive accumulation of activity within the 
myocardium accompanied by blood pool clearance. 2) Ac-
tivity maxima were defined within these ellipses along 60 
radii, commencing at the posterior intersection of the left 
and right ventricular free walls. 3) A 3 x 3 voxel region of 
interest around each area of maximal activity was used to 
define myocardial regions of interest, representing 60 regions 
for each plane. 4) Finally, using the spatial coordinates of 
these regions of interest, regional tissue tracer activity was 
determined for all frames yielding time-activity curves for 60 
regions in each short-axis cardiac plane. 
From the resultant decay-corrected C-11 acetate time-
activity curves (Fig. 2), C-ll clearance rate constants (k) 
were obtained by least-square monoexponential curve fitting 
as previously described (7). Comparison of C-ll clearance 
rate constants obtained using these reorientation and re-
gional analysis algorithms with those derived from analysis 
of the primary transaxial data revealed concordant results, 
validating this approach (2). 
Using an analysis approach proposed by Patlak et al. 
(34,35) and adapted for quantification of myocardial glucose 
utilization by Gambhir et al. (10), blood pool and myocardial 
F-18 fluorodeoxyglucose time-activity curves were used to 
calculate myocardial glucose utilization. The approach of 
Patlak et al. (34,35) represents a graphic analysis of F-18 
fluorodeoxyglucose kinetics based on the measurement of 
F-18 activity in blood pool and myocardial regions of inter-
est. The blood pool region of interest including ~4 voxels 
was defined in an early frame of the dynamic series and was 
confined to one to two basal planes to minimize myocardial 
spillover into this region of interest at late time points. The 
use of a basal ventricular blood pool region of interest for 
determination of the arterial input function of F-18 fluorode-
oxyglucose into the myocardium has been validated for the 
normal human heart by Gambhir et al. (10). 
The Patlak curve describes the relation between C/Cb 
and fCb(o_t)/Cb, where Ct is the decay-corrected myocardial 
activity and Cb is the decay-corrected blood pool activity at 
any given time t; fCb(o-t) is the integral of decay-corrected 
blood pool activity from time zero to time t and serves as an 
index of the arterial input function of F-18 fluorodeoxyglu-
cose into the myocardium (34,35). Because F-18 fluorode-
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Figure 2. Upper panel, Decay-corrected time-activity curves aver-
aged for myocardial (+) and blood pool (e) in the 60 regions of 
interest analyzed within this plane are displayed. Lower panel, All 60 
such curves were used for analysis of C-II clearance kinetics in each 
of 12 cardiac short-axis planes encompassing the entire heart. 
Monoexponential curve fitting of the myocardial time-activity curve 
was performed, beginning after the rapid clearance phase of the 
blood pool time-activity curve (upper panel, vertical line). 
oxyglucose-6-phosphate accumulates in tissue as a function 
of uptake and phosphorylation of F-18 fluorodeoxyglucose 
(8), this relation becomes linear after equilibration of free 
tissue F-18 fluorodeoxyglucose (Fig. 3). The linear part of 
this plot was determined with a derivative approach. Myo-
cardial glucose utilization rates were derived by mUltiplying 
the slope of this linear part ofthe plot by the average ofthree 
plasma glucose measurements obtained at the beginning, 
mid-point and end of the F-18 fluorodeoxyglucose study 
(converted to JLmollliter) and then dividing by the "lumped 
constant." The lumped constant has been experimentally 
derived and reflects the differences in myocardial handling of 
glucose and F-18 fluorodeoxyglucose. In our algorithm, the 
lumped constant was set at 0.67, as defined in previous 
animal studies (18). 
The C-J1 clearance rate constant data and F-18 fluoro-
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Figure 3. An example of a typical Patlak curve for one sector of a 
mid-ventricular plane. Analysis of F-18 ftuorodeoxyglucose uptake 
kinetics, using Patlak graphic analysis (34), permitted evaluation of 
myocardial glucose utilization in 60 regions of interest/plane and for 
12 cardiac short-axis planes encompassing the entire heart. Cp(t) = 
instantaneous tissue activity at time t; Cb(t) = instantaneous blood 
pool activity at time t; l-Cb(o-t) = the integral of blood pool 
activity from time zero to time t. 
deoxyglucose uptake data were averaged for quadrants 
representing 15 sectors of 6° each and assigned to the 
anterior, lateral, inferior and septal walls with use of a 
standardized polar map display format (2,36). Data were also 
averaged for all 60 sectors in the two apical, five mid-basal 
and five basal planes to provide assessment of regional 
variation in metabolism from apex to base of the left ventri-
cle. 
Statistical analysis. Values are given as mean values ± 
SD. The comparability of substrate availability, hormone 
levels and hemodynamic variables between radionuclide 
imaging studies and between the two study protocols was 
assessed with analysis of variance (ANOV A). Where signif-
icance was suggested by this analysis, the level of signifi-
cance was determined with use of Student's t test for paired 
data with Bonferroni's correction for multiple analyses. 
Regional variation of C-ll clearance rate constants and 
myocardial glucose utilization was assessed by analysis of 
variance for repeated measures, with correction using 
Scheffe's F test method. Statistical significance was indi-
cated by a p value ::;0.05. 
Results 
Metabolic and hemodynamic conditions (Table 1). Sub-
strate, hormonal and hemodynamic conditions during each 
imaging sequence are compared in Table 1. These data 
demonstrate little difference in metabolic conditions at the 
time of C-11 acetate and F-18 fluorodeoxyglucose imaging 
during each study. In the insulin clamp protocol without lipid 
emulsion infusion, the heart rate-blood pressure product was 
slightly higher at the time of F-18 fluorodeoxyglucose imag-
ing than during the acquisition of the C-ll acetate data (p < 
0.05). The large standard deviation of human growth hor-
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Table 1. Metabolic and Hemodynamic Conditions 
Clamp C-lI 
Clamp + FFA Clamp + FFA 
Acetate Clamp FDG p Value C-lI Acetate FDG p Value 
Glucose (mg/dl) 86 ± 6 85 ± 7 NS 87 ± 8 84 ± 7 NS 
FFA(mM) 0.14 ± 0.05 0.12 ± 0.04 NS 0.38 ± 0.17* 0.52 ± 0.24t <0.005 
Lactate (mg/dl) 0.79 ± 0.16 0.75 ± 0.75 NS 0.67 ± 0.15 0.71 ± 0.13 NS 
Insulin (mUlliter) 90 ± 19 % ± 18 NS 108 ± 16 105 ± 34 NS 
Glucagon (pg/ml) 54 ± 18 55 ± 23 NS 68 ± 21 69 ± 18 NS 
HGH (ng/ml) 1.11 ± 0.47 4.29 ± 5.14 NS 1.02 ± 0.30 2.15 ± 2.75 NS 
NE (pg/mJ) 279 ± 65 276 ± 65 NS 257 ± 41 252 ± 45 NS 
Epi (pg/ml) 84 ± 25 % ± 34 NS 94 ± 18 91 ± 23 NS 
RPP 6,593 ± 892 7,010 ± 862 <0.05 6,833 ± 1,134 7,048 ± 1,312 NS 
*p < 0.001 compared with during clamp C-II acetate study; tp < 0.001 compared with during fluorodeoxyglucose (FDG) study. Epi = epinephrine; FDG = 
F-18 fluorodeoxyglucose; FFA = free fatty acid; HGH = human growth hormone; NE = norepinephrine; RPP = heart rate-blood pressure product. 
mone levels during the fluorodeoxyglucose studies both with 
and without free fatty acid infusion reflects high values in a 
single subject who fell asleep during both studies. In this 
subject, there was no evidence of hypoglycemia or fluctua-
tion in other substrates or hormones to explain this change. 
Comparison of the substrate, hormonal and hemody-
namic conditions in the two protocols showed significantly 
higher free fatty acid levels in the protocol with free fatty 
acid infusion compared with values during the protocol 
involving the hyperinsulinemic-euglycemic clamp study 
without free fatty acid infusion (p < 0.001). There was no 
significant difference in the other measured variables. Paired 
comparison of plasma glucose and insulin levels during both 
C-l1 acetate and both F-IS fluorodeoxyglucose imaging 
studies in each individual revealed no significant differences 
and values approximated the target levels determined in the 
study design (Table 1). 
Variation oJC-ll Clearance Kinetics 
Regional C-11 clearance (Table 2). Technically adequate 
C-11 acetate studies were available in all nine subjects during 
the free fatty acid infusion protocol, but one C-ll acetate 
study obtained during the clamp protocol without free fatty 
acid infusion could not be processed because of a system 
malfunction during data acquisition. Comparison between 
studies was thus based on paired data from eight subjects. 
Regional variation in C-ll clearance rate constants was 
assessed for all 17 studies that could be analyzed. 
There was only minor (5% to 9%) regional variation in 
C-ll clearance rate constants within the left ventricle (Table 
2). However, C-11 clearance rate constants were slightly 
higher in the septal quadrant compared with the lateral 
quadrant (p < 0.05 for the study with elevated free fatty acid 
levels). Similarly, on paired comparison in individual sub-
jects, C-li clearance rate constants were significantly higher 
in the basal and mid-basal regions than in the apex both with 
and without elevated free fatty acid levels (p < 0.05). 
Effect of substrate availability on myocardial C-ll acetate 
clearance kinetics (Table 3). There was a small but signifi-
cant increase in global C-Il clearance rate constants with the 
addition of free fatty acid infusion (p < 0.05). The increase 
was most marked in the septal wall. On average, C-ll 
clearance rate constants were only 2.5% higher in the septal 
quadrant than in the lateral quadrant during the hyperinsu-
linemic-euglycemic clamp protocol without free fatty acid 
infusion (p = NS). This difference was less than that 
observed when free fatty acid levels were elevated. In the 
clamp protocol with free fatty acid infusion, septal C-ll 
clearance rate constants averaged 9% higher than those in 
the lateral quadrant (p < 0.05) (Fig. 4). 
Table 2. Regional Variation in C-ll Acetate Clearance Rate Constants (klmin) 
Global Septum Anterior Lateral Inferior Basal Mid-Basal Apex 
Clamp 0.053 ± 0.006 0.055* ± 0.007 0.056* ± 0.007 0.054 ± 0.007 0.052 ± 0.005 o.om ± 0.007 0.054t ± 0.006 0.050 ± 0.005 
(n = 8) 
Clamp + FFA 0.058 ± 0.006 0.061t ± 0.006 0.060 ± 0.009 0.056 ± 0.006 0.057 ± 0.006 0.059§ ± 0.006 0.058§ ± 0.006 0.054 ± 0.008 
(n = 9) 
p Value <0.05 NS NS NS NS NS NS NS 
*p < 0.05 compared with inferior quadrant in clamp study; tp < 0.05 compared with apex in clamp study; tp < 0.05 compared with lateral quadrant in clamp 
study with free fatty acid (FFA) infusion; §p < 0.05 compared with apex in clamp study with free fatty acid infusion. Analysis of variance for repeated measures; 
Clamp = hyperinsulinemic-euglycemic clamp. 
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Regional variation (Table 3). Technically adequate P-18 
ftuorodeoxyglucose studies were available in all nine sub-
jects during the free fatty acid infusion protocol, but one 
study obtained during the clamp protocol without free fatty 
acid infusion could not be analyzed because of patient 
motion during data acquisition. This was a different patient 
from the patient with a technically inadequate C-ll acetate 
study. Comparison between F-18 ftuorodeoxyglucose stud-
ies was thus based on paired data from eight subjects. 
Regional variation of F -18 ftuorodeoxyglucose kinetics 
within studies was assessed for all 17 studies that could be 
analyzed. 
In both clamp protocols, glucose utilization was lower in 
the septal than in the lateral quadrant. Glucose utilization 
was 13% lower in the septum than in the lateral wall both 
without and with lipid infusion (0.34 vs. 0.39 JLmol/g per min, 
respectively, p < 0.05; and 0.33 vs. 0.38 JLmol/g per min, 
Figure 4. Polar maps of pooled data from the eight C-ll acetate 
studies that could be analyzed during a hyperinsulinemic-
euglycemic clamp protocol (Clamp) and all studies during a 
combined hyperinsulinemic-euglycemic clamp protocol with free 
fatty acid infusion (Clamp + FF A) are displayed, with each polar 
map being normalized to its maximum (white on the color scale). 
Relatively increased C-ll clearance rate constants (k/min) (left) 
from the anterior and septal regions compared with the inferior 
and lateral regions were apparent. The inhomogeneity of C-ll 
clearance was more obvious for the studies with free fatty acid 
infusion. Glucose utilization (right) was lower in the septum than 
in the lateral quadrant. 
respectively, p < 0.05). Also, Patlak-derived myocardial 
glucose utilization rates were higher in the basal regions than 
in the apex (Fig. 4). 
Effect of substrate availability on myocardial glucose utili-
zation (Table 3). Myocardial glucose utilization rates in 
individual studies were similar in the clamp studies without 
and with lipid emulsion infusion. Global myocardial glucose 
utilization rates averaged 0.35 ± 0.12 JLmol/g per min in the 
protocol without lipid emulsion infusion and 0.34 ± 0.08 
JLmol/g per min in the protocol with lipid emulsion infusion 
(p = NS). Thus, under controlled metabolic conditions of 
glucose and insulin loading, myocardial glucose utilization 
was not significantly reduced despite the presence of signif-
icantly elevated free fatty acid levels after lipid emulsion 
infusion. Neither was there a significant change in regional 
glucose utilization rates (Table 3). The glucose utilization 
rate in the septal quadrant averaged 87% ofthat in the lateral 
quadrant in both study protocols. 
Table 3. Regional Myocardial Glucose Metabolism (in JLmol/g per min) as Determined by Patlak Analysis 
Global Septum Anterior Lateral Inferior Basal Mid-Basal Apex 
Clamp 0.35 ± 0.12 0.34 ± 0.13 0.35 ± 0.13 0.39* ± 0.13 0.33 ± 0.12 0.36t ± 0.12 0.35t ± 0.09 0.30 ± 0.11 
(n = 8) 
Clamp + FFA 0.34 ± 0.08 0.33 ± 0.08 0.35 ± 0.\0 0.38:J: ± 0.10 0.35 ± 0.10 0.35 ± 0.12 0.35§ ± 0.09 0.31 ± 0.10 
(n = 9) 
p Value NS NS NS NS NS NS NS NS 
'p < 0.05 compared with septal, anterior and inferior quadrants in clamp study; tp < 0.05 compared with apex in clamp study; :J:p < 0.05 compared with septal 
quadrant in clamp study with free fatty acid (FFA) infusion; §p < 0.05 compared with apex in clamp study with free fatty acid infusion. Analysis of variance for 
multiple analyses; Clamp = hyperinsulinemic-euglycemic clamp. 
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Discussion 
Because ischemic myocardium preferentially uses glu-
cose as a metabolic substrate (37-39), characterization and 
comparison of regional myocardial oxidative and glucose 
metabolism using positron emission tomography may pro-
vide unique evaluation of the metabolic concomitants of 
ischemic heart disease. Such comparison must assume ho-
mogeneous regional substrate utilization within the normal 
heart or be accompanied by a knowledge of the normal 
regional variation in myocardial metabolism and the factors 
that affect it. 
This study evaluated regional oxidative and glucose me-
tabolism using sophisticated positron emission tomographic 
metabolic imaging approaches and found minor but statisti-
cally significant regional heterogeneity of metabolism within 
the normal human heart under standardized conditions of 
substrate availability (Fig. 4). These data have important 
implications for evaiuation of myocardial metabolism using 
cardiac positron emission tomography. 
Regional heterogeneity in the physiology of the normal 
heart. Although it is intuitive that physiologic variables 
should be uniform throughout the normal myocardium, some 
elegant experimental data show that this is not the case. 
Small but significant variation in regional myocardial blood 
flow. as assessed by the microsphere technique (40-42), 
occurs within the normal heart. Similarly, there is also 
evidence of heterogeneity in the pattern of myocardial 
contraction within normal hearts (43). These small physio-
logic variations in regional perfusion and contractile function 
are unlikely to be detected with routinely used nuclear 
medicine techniques because of the apparent variation re-
lated to the effects of tissue attenuation, limited spatial and 
temporal resolution, partial volume effect and cardiac mo-
tion (36,44,45). However, just as advances in ultrafast com-
puted tomography (46) and rapid cine nuclear magnetic 
resonance imaging (47) have provided evidence of variability 
of regional left ventricular function in the normal heart, 
recent advances in positron emission tomographic imaging 
hardware and analysis software have provided the potential 
to assess the normal regional variation in myocardial metab-
olism. 
Regional variation of myocardial oxidative metabolism. In 
animal studies (4), there is a close correlation between C-ll 
clearance rate constants and global myocardial oxygen con-
sumption. In human studies (6,7), global C-ll clearance rate 
constants are closely correlated with independent variables 
of myocardial oxygen demand, such as the left ventricular 
rate-pressure product. Thus, analysis of regional C-ll clear-
ance kinetics should provide assessment of regional oxida-
tive metabolism in the normal human heart. 
We previously documented (2) minor but statistically 
significant regional variation in C-ll clearance in fasting and 
glucose-loaded individuals. The data from the nine normal 
subjects we studied during a hyperinsulinemic-euglycemic 
clamp protocol support our previous findings suggesting 
slightly increased oxidative metabolism in the septum com-
pared with the lateral wall (Table 2). Henes et al. (6), using 
region of interest analysis of single transverse images, ob-
served higher C-ll clearance rates in the septum of the 
normal human heart under rest conditions and after dobu-
tamine infusion. Although the differences were not statisti-
cally significant, Gropler et al. (13) also demonstrated higher 
C-ll clearance rates in the septum than in the lateral wall in 
seven subjects studied under fasting conditions. These data 
support the presence of segmental variation, albeit small, in 
regional oxygen consumption circumferentially within the 
normal human heart. 
The etiology and importance of this minor regional 
variation in oxidative metabolism are unclear. A possible 
explanation includes regional variation in myocardial work. 
The higher C-l1 clearance rates in the basal regions of the 
left ventricle compared with the apex are consistent with 
data (46) suggesting higher stroke volumes in the basal 
regions of the heart than in more apical segments, findings 
that may be associated with relatively increased wall stress 
and oxygen demand in the basal regions. Although the 
circumferential homogeneity of regional myocardial work 
has not been extensively characterized, one study (47) using 
rapid cine nuclear magnetic resonance imaging found that 
fractional thickening was greater in the posterior than in the 
anterior wall. These data are at variance with the higher C-11 
clearance rates observed in the anterior than in the inferior 
quadrant in our normal subjects (Table 3). 
Regional variation of myocardial glucose utilization. Re-
gional variation of glucose metabolism in the normal human 
heart has not been extensively studied. Myocardial biopsy 
studies (48-50) in animals found a transmural gradient of 
glycogen stores and glycolytic enzymes. The subendocar-
dium contains more glycogen and has higher levels of 
glycolytic enzymes and increased phosphorylase activity 
compared with the subepicardium. Although these factors 
may alter glucose utilization across the left ventricular 
myocardium, clearly they cannot be resolved by current 
positron emission tomographic imaging technology. How-
ever, regional variation of exogenous glucose utilization 
among the walls of the left ventricle has been observed in the 
rat (51). Autoradiographic studies (51) using C-14 deoxyglu-
cose showed a 13% higher tracer uptake in the lateral wall 
compared with the interventricular septum. Although spe-
cies differences may exist, previous studies (11-13) with 
qualitative and semiquantitative evaluation of myocardial 
F -18 fluorodeoxyglucose uptake have also suggested the 
presence of decreased glycolytic flux in the septum and 
anterior wall compared with the lateral wall under fasting 
conditions. Specifically, Gropler et al. (13) found that F-18 
fluorodeoxyglucose retention in the septum and anterior wall 
was only 80% of that in the lateral and posterior walls, 
suggesting decreased exogenous glucose utilization in these 
regions. These semiquantitative data were in keeping with 
previous qualitative observations (11,12) of decreased F-18 
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fluorodeoxyglucose uptake in the septum of the heart in 
individuals after fasting. 
The quantitative data obtained in our normal subjects 
under standardized metabolic conditions support the validity 
of these previous observations and suggest th!! presence of 
significant regional variation in glucose metabolism. As also 
concluded by Gropler et al. (13), the lower glucose utiliza-
tion in the septum than in the lateral wall cannot be readily 
explained by decreased metabolic demand because the C-11 
clearance rate constants were not concomitantly, decreased. 
Indeed, C-11 clearance kinetics in both study groups sug-
gested that tricarboxylic acid cycle flux was slightly greater 
in the septum than in the lateral wall. Additionally, Gropler 
et al. (13) found no significant alteration in regional perfu-
sion, as assessed by positron emission tomography with 
oxygen-15 water, to explain the relatively decreased F-18 
flllorodeoxyglucose retention observed in the septum. 
Although there was discordance in the circumferential 
distribution of oxidative metabolism and glucose utilization 
as determined by positron emission tomography, there was a 
concordant decrease in both C-11 clearance rate constants 
and glucose utilization from base to apex in the left ventricle. 
These changes probably reflect decreased energy demand in 
the apical regions as expected by lower stroke volumes in 
these regions (46). 
Effect of substrate availability on c·n acetate and F ·18 
ftuorodeoxyglucose kinetics. Previous investigations (5) have 
suggested that C-11 acetate is a preferred substrate for the 
tricarboxylic acid cycle because its oxidation appears to be 
largely independent of plasma substrate availability unlike 
that of alternative metabolic tracers such as C-ll palmitate 
and F-18 fluorodeoxyglucose. However, there are experi-
mental data (17) suggesting that myocardial oxygen con-
sumption is dependent on substrate utilization by the heart. 
In dogs, the utilization of free fatty acids increased myocar-
dial oxygen consumption significantly compared with mea-
surement after stimulation of glucose metabolism and inhi-
bition of free fatty acid metabolism (17). These data are 
compatible with the lower production of adenosine triphos-
phate (32 vs. 38 moles) per mole of oxygen consumed during 
oxidation of free fatty acids compared with that of carbohy-
drates. In keeping with these data, comparison of paired 
studies with and without infusion of free fatty acids in each 
subject revealed a small but significant increase in C-11 
clearance (p < 0.05) in the presence of higher free fatty acid 
levels. Our finding of faster global C-ll clearance in the 
study with elevated free fatty acid levels is supported by the 
study of Armbrecht et al. (7), who observed a small decrease 
in C-11 clearance after oral glucose loading compared with 
fasting studies in four patients. In our subjects, the increase 
in C-l1 clearance rates after free fatty acid infusion was most 
marked in the septal quadrant where the average C-ll 
clearance rate constant increased from 0.055 to 0.061 per 
min. 
Under fasting conditions, myocardial glucose utilization 
is inhibited by high circulating free fatty acid levels (20). 
However, in this study with glucose loading, elevation of 
free fatty acid levels did not change global or regional 
myocardial glucose utilization significantly, suggesting that 
insulin has an important modulating effect on myocardial 
glucose utilization that is largely independent of its role in 
decreasing free fatty acid levels. This effect is supported by 
animal data (52,53) that suggest that although insulin is not 
required for myocardial uptake of glucose or F-18 fluorode-
oxyglucose, myocardial glucose metabolism is markedly 
augmented in the presence of insulin. 
Implications. The presence of relatively decreased glu-
cose Utilization in the septum compared with the lateral wall 
is not readily explained by regional variation in perfusion 
(13) or energy demand based on previous studies (47) of 
regional contractility and the small relative increase in septal 
C-11 clearance rates demonstrated in our study. However, 
higher free fatty acid utilization by the anteroseptal region 
could explain both slightly higher oxygen consumption and 
the lower glucose utilization in the septum and anterior wall 
by virtue of the higher oxygen requirements of. beta-
oxidation compared with glycolysis (17). Similar sophisti-
cated quantitative analysis of regional myocardial free fatty 
acid utilization using C-ll palmitate is warranted to evaluate 
this hypothesis further. 
We previously reported (2) that the interpatient variabil-
ity of C-ll clearance rate constants was at least twofold 
higher in fasting patients than in patients after glucose 
loading or under insulin-clamped conditions. This finding 
possibly reflects the heterogeneity in substrate availability 
under fasting conditions. In the current study, the inhomo-
geneity of myocardial F-18 fluorodeoxyglucose accumula-
tion during glucose loading both with and without elevated 
free fatty acid levels was less than that observed by Gropler 
et al. (13) under fasting conditions. They found that relative 
F-18 fluorodeoxyglucose retention in the septum was only 
75% of that in the lateral wall. In our subjects studied during 
glucose and insulin loading, the Patlak-denved glucose ex-
traction rate in the septal quadrant was 87% of that in the 
lateral quadrant. This was similar to the value of 88% 
reported by Gropler et al. (13) in five patients studied after an 
oral glucose load. 
The findings of this study suggest that standardization of 
the metabolic conditions by use of glucose and insulin 
infusion in individuals undergoing quantitative positron 
emission tomographic metabolic studies minimizes the re-
gional inhomogeneity in F-18 fluorodeoxyglucose uptake and 
C-ll clearance. These effects most probably reflect the effect 
of insulin in simultaneously increasing myocardial glucose 
utilization and suppressing free fatty acid levels. Although 
the clamp technique used in this study achieves steady state 
plasma glucose levels in an acceptable time frame «45 min) 
in normal individuals without elevation of baseline plasma 
glucose levels, it may not be practical for clinical studies in 
patients with diabetes mellitus who may have elevated 
fasting glucose levels and variable degrees of insulin sensi-
tivity. We are currently utilizing a simplified protocol of 
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glucose and insulin infusion for clinical studies with supple-
mental bolus infusions of insulin in individuals with elevated 
baseline plasma glucose levels. 
Technical Considerations 
C·ll acetate as a tracer of oxidative metabolism. The C-II 
clearance rate constants represent a rate of change in activ-
ity and are thus insensitive to partial volume effects. Conse-
quently, correction for partial volume effects, which would 
have required accurate determination of regional wall thick-
ness, Was not performed. Spillover of blood pool activity 
into the septal myocardial region of interest would be 
expected to be higher than for the lateral wall because of the 
presence of the adjacent right and left ventricular cavities. 
Because blood pool C-II activity decreases rapidly and has 
reached relatively constant low levels during the interval 
used for curve fitting, the effects of spillover would be most 
marked in the tail of the C-II acetate time-activity curve. 
The effect of increased spillover would be to decrease the 
apparent C-Il clearance rate constant. Thus, although spill-
over correction was not done, it is not possible to explain the 
increased septal C-ll clearance rate constants observed in 
this study on the basis of bidirectional spillover of blood pool 
activity into the septum. 
The possibility that the observed variation in regional 
C-ll clearance rate constants represents the effects of sys-
tematic errors introduced by the reorientation and analysis 
algorithms cannot be excluded. However, previous valida-
tion studies (2) in normal subjects comparing C-ll clearance 
rate constants derived from analysis of primary transaxial 
data with those obtained from reoriented short-axis data 
showed highly concordant global and regional results. 
F·18 fluorodeoxyglucose as a tracer of glucose metabolism. 
Because F-18 fluorodeoxyglucose represents a glucose ana-
log that behaves similarly but not identically to glucose, it 
may not perfectly trace glucose metabolism. The Michaelis-
Menten kinetic constants describing the affinity of glucose or 
similar compounds for transmembrane transport and phos-
phorylation differ for glucose and F-IS fluorodeoxyglucose. 
These biochemical differences are corrected for by a 
"lumped constant" in the tracer kinetic model for F-IS 
fluorodeoxyglucose tissue retention (54). Although experi-
mental studies (9) in the canine heart have shown that this 
"lumped constant" is stable under a range of physiologic 
conditions, no data are available about possib~e regional 
differences of this constant within the left ventricle. Such 
variation could explain regional variation in F -18 fluorode-
oxyglucose uptake tnat does not reflect a true variation in 
glucose metabolism, but it is technically difficult to establish. 
The Patlak analysis of F-lS fluorodeoxyglucose kinetics 
used in this study assumed the rate constant k4' representing 
dephosphorylation of F-18 fluorodeoxyglucose-6-phosphate, 
to be zero throughout the heart (34,35). Although actual 
fitting of this rate constant may provide more accurate 
estimates of myocardial glucose utilization, it calls for ac-
quisition times > 120 min (10). The added imaging time 
would have led to a total study period of >4 h, which was 
believed to be longer than could be reasonably tolerated by 
our subjects. Setting the rate constant k4 at zero is a 
reasonable approximation because there is evidence (9,10) 
that the dephosphorylation of F-18 fiuorodeoxyglucose-6-
phosphate in the myocardium is extremely slow. Although 
the absolute values of glucose utilization derived from Patlak 
analysis may not be identical witlitrue exogenous glucose 
utilization, the main purpose of this study was to compare 
regional myocardial glucose metabolism within individual 
subjects. Thus, trends rather than absolute values were 
considered important. The possibility that there may be 
regional heterogeneity in dephosphorylation of F-IS fluoro-
deoxyglucose-6-phosphate within the left ventricle, which 
would be reflected in regional variation in the rate constant 
k4' cannot be excluded and needs further evaluation. 
The absence of apparent change in glucose utilization by 
the heart after elevation of free fatty acid levels may be due 
to a change in the metaboiic fate of exogenous glucose. 
Under fasting conditions, wheQ free fatty acid levels are 
elevated, :570% of extracted glucose is stored as glycogert 
(19). The combination of simultaneous glucose and free fatty 
acid infusion used in this study could have led to a transient 
disturbance of the eqUilibrium among glycogenesis, glycogen 
degradation and glycolysis. The availability offree fatty acid 
as a myocardial substrate may have decreased glycolysis and 
thereby increased availability of glucose for glycogenesis. 
Because F-18 fluorodeoxyglucose traces only the initial 
uptake and phosphorylation of glucose by the hexokinase 
reaction, such changes could theoretically be accompanied 
by no apparent change in net exogenous glucose utilization. 
Without direct invasive estimation of glucqse oxidation rates 
in the myocardium, this possibility could not be evaluated by 
this study and calls for further evaluation in animals and 
humans. 
Conclusion. This study quantitatively evaluated the re-
gional homogeneity of myocardial glucose utilization, as 
determined by Patlak analysis of F-IS fluorodeoxyglucose 
uptake kinetics in the normal human heart under standard-
ized conditions of glucose and insulin loading. Small but 
statistically significant segmental inhomogeneity in myocar-
dial glucose utilization was observed. This variation was 
similar but less marked than previously found by semiquan-
titative analysis of regional myocardial F-18 fluorodeoxyglu-
cose retention in fasting individuals. The inhomogeneity in 
F-18 fluorodeoxyglucose uptake kinetics was accompanied 
but not explained by minor regional variation in C-II clear-
ance kinetics. The etiology and especially the biochemical 
mechanism of these findings are unclear and require further 
assessment. 
The effects of elevated free fatty acid levels on regional 
and global myocardial metabolism, which are significant 
under fasting conditions (13,19), were small in magnitude 
during concomitant glucose and insulin loading. These data 
suggest that the use of insulin and glucose infusion to 
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standardize the metabolic status of patients undergoing 
positron emission tomographic metabolic studies minimizes 
regional inhomogeneity of myocardial oxidative and glucose 
metabolism. Such standardization is important if these tech-
niques are used to describe changes after therapeutic inter-
ventions or for comparison with a normal data base. Char-
acterization of the three-dimensional distribution of 
myocardial glucose and oxidative metabolism using the 
approaches described in this study should provide unique 
characterization of the metabolic changes associated with 
ischemic heart disease and other cardiac diseases. 
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